Observational Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Oct 14, 2019; 25(38): 5862-5882
Published online Oct 14, 2019. doi: 10.3748/wjg.v25.i38.5862
Figure 1
Figure 1 Spearman’s correlation coefficients between domains and summary measures of the different quality of life measures. SF-36: Short-form 36; EQ-5D: Euro quality of life – 5 dimensions; EQ-VAS: EQ-5D visual analog scale; IBDQ: Inflammatory bowel disease questionnaire.
Figure 2
Figure 2 Healthcare resource utilization by time since the first diagnosis of moderate to severe inflammatory bowel diseases.
Figure 3
Figure 3 Most frequently used drugs for inflammatory bowel diseases (overall frequency ≥ 5%). A: Drugs used by patients with Crohn’s disease (total and by disease activity); B: Drugs used by patients with ulcerative colitis (total and by disease activity). Note: % refers to patients using at least one medicine. CD: Crohn’s disease; UC: Ulcerative colitis.

  • Citation: Parra RS, Chebli JM, Amarante HM, Flores C, Parente JM, Ramos O, Fernandes M, Rocha JJ, Feitosa MR, Feres O, Scotton AS, Nones RB, Lima MM, Zaltman C, Goncalves CD, Guimaraes IM, Santana GO, Sassaki LY, Hossne RS, Bafutto M, Junior RL, Faria MA, Miszputen SJ, Gomes TN, Catapani WR, Faria AA, Souza SC, Caratin RF, Senra JT, Ferrari ML. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol 2019; 25(38): 5862-5882
  • URL: https://www.wjgnet.com/1007-9327/full/v25/i38/5862.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v25.i38.5862